Company intelligence / Profile preview

Aplos Medical

Eden Prairie, Minnesota, United Statesaplosmed.com ↗

Ownership: Private
Development stage: Other

Overview

Aplos Medical has developed Omega PF, a novel dual-modality implantable medical device for GERD. The first successful human implantation was reported in November 2023. Early results indicate the procedure is simpler and potentially safer than traditional surgical options like Nissen fundoplication. The patient from the initial trial was satisfied with outcomes and experienced no major complications. Broader clinical validation is ongoing.

Therapeutic areas: Gastroenterology
Modalities: DeviceDual-modality device (integrates two treatment approaches for GERD)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

Omega PF

IND

Indications: Gastroesophageal reflux disease

Beyond the preview

Go deeper on Aplos Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aplos Medical.

Explore the full profile